Literature DB >> 15261228

A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test.

Joong-Seok Kim1, Kwang-Soo Lee, Yeong-In Kim, Yoshiko Tamai, Reiko Nakahata, Hideki Takami.   

Abstract

The effects of three antiplatelet drugs, aspirin, clopidogrel and cilostazol, were examined and compared using a quantitative bleeding time (QBT) test apparatus. In 12 healthy adult male subjects, a QBT test and platelet aggregation test were performed before and after medication. Cilostazol was found to be as effective as aspirin and clopidogrel in inhibiting platelet aggregation. Following the oral administration of aspirin and clopidogrel for 7 days, the bleeding time was significantly prolonged. In contrast, none of these QBT parameters were altered by the cilostazol treatment. This suggests that cilostazol has potent efficacy in inhibiting platelet aggregation without prolonging the bleeding time and changing the bleeding pattern.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261228     DOI: 10.1016/j.jocn.2003.10.022

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Antiplatelet Effect of Sequential Administration of Cilostazol in Patients with Acetylsalycilic Acid Resistance.

Authors:  Muzaffer Cakmak; Bora Demircelik; Mustafa Cetin; Zehra Cetin; Serhat Isık; Hulya Cıcekcıoglu; Feridun Vasfi Ulusoy; Beyhan Eryonucu
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

2.  Comparison of long-term efficacy and safety between cilostazol and clopidogrel in chronic ischemic stroke: a nationwide cohort study.

Authors:  Tsong-Hai Lee; Yu-Sheng Lin; Chia-Wei Liou; Jiann-Der Lee; Tsung-I Peng; Chi-Hung Liu
Journal:  Ther Adv Chronic Dis       Date:  2020-07-30       Impact factor: 5.091

Review 3.  Medical management for chronic atherosclerotic peripheral arterial disease.

Authors:  Farzana Nawaz Ali; Teresa L Carman
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

Review 4.  Cilostazol for Secondary Prevention of Stroke: Should the Guidelines Perhaps Be Extended?

Authors:  George Galyfos; Argyri Sianou
Journal:  Vasc Specialist Int       Date:  2017-09-30

5.  Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease.

Authors:  Sangmo Hong; Woo Je Lee; Cheol-Young Park
Journal:  Endocrinol Metab (Seoul)       Date:  2022-04-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.